Recent Evolution in Antiviral Drug Resistance
Antiviral drugs are specifically used to treat viral infections, instead of bacteria. Most antivirals are used for certain viral infections, while a wide range of antiviruses are effective against a wide range of viruses. Viruses are the tinier germs that can cause several infectious diseases such as flu, common cold, and warts. Viruses can also cause severe illnesses, including smallpox, HIV/AIDS, and Ebola. Viruses reproduce inside cells and able to enter into any living, healthy cells and multiply and produce other viruses like themselves. Different viruses attack specific cells in the body such as liver, brain, skin, blood and also reproductive, respiratory, and gastrointestinal systems.
Antiviral Drug Resistance industry is anticipated to be the world’s largest most significant revenue contributor during the forthcoming years, owing to several advancements in the field of biotechnology due to increased emphasis on R&D activities. The growth is driven by factors such as increased prevalence of HIV and hepatitis and supportive policies by the government to tackle burden of the diseases.
The major key players operating in the antiviral drug resistance industry:
- Danaher
- Abbott
- BD
- F. Hoffmann-La Roche Ltd
- Trinity Biotech
- Seimens AG
- bioMĂ©rieux SA
- Bio-Rad Laboratories, Inc
- AccuBioTech Co., Ltd.
- ACON Laboratories, Inc.
The viral infectious diseases is anticipated to remain a major public health problem in the coming decades, which poses a threat to both national and international health security. Endemic diseases including, human immunodeficiency virus infection and acquired immune deficiency syndrome (HIV/AIDS) will continue to challenge public health. For the early detection and rapid response, high level of awareness is required across the region.
The prevalence of virus infections such as hepatitis has increased during recent years across the globe. Hepatitis causes liver damage and inflammation that can also damage other organs. It is a major global health problem that can cause chronic infection and also upsurge the higher risk of death from cirrhosis and liver cancer. Hepatitis can be categorized as hepatitis A, B, C, D, and E that spread through different causes. According to the WHO (World Health Organization), the prevalence of Hepatitis B is the highest in the African and Western Pacific Region, where 6.1% and 6.2% of the adult population is infected respectively.
Thus, the antiviral drug resistance industry is expected to grow in the coming years, owing to factors such as rise in the incidences of hepatitis diseases and increasing prevalence of HIV/AIDS.